Brimonidine triples trabeculectomy failure
- American Journal of Ophthalmology published a 501-eye cohort showing glaucoma patients on pre-op brimonidine had markedly worse trabeculectomy pressure-control outcomes after surgery. - The key number was a 2.87 hazard ratio for failure from high IOP — basically a near-tripling versus eyes not exposed. - That matters because surgeons already worry chronic drops inflame conjunctiva — and this points to one drug as a specific risk.
Trabeculectomy is glaucoma’s classic pressure-lowering surgery — the move you make when drops and lasers are no longer enough. The whole point is to build a durable drainage pathway that keeps eye pressure down for years. The problem is that the tissue you operate on has often been soaking in topical meds for a long time before surgery. Now a new American Journal of Ophthalmology paper says one of those meds, brimonidine, may be especially bad news before trabeculectomy, with a near threefold increase in failure driven by high postoperative pressure. (ajo.com) ### What is brimonidine, exactly? Brimonidine is an alpha-2 agonist eye drop used to lower intraocular pressure in glaucoma and ocular hypertension. It is common, familiar, and often added when first-line drops are not enough. That is why this matters — the signal is not about some exotic rescue therapy. It is about a routine bottle many glaucoma patients may already be using on the way to surgery. (mayoclinic.org) ### What did the new study actually look at? This was a retrospective observational study from a single U.S. academic center covering January 2015 through March 2022. The investigators looked at 501 eyes from 501 adults who underwent primary trabeculectomy and mapped preoperative glaucoma medications across 43 formulations so exposur(mayoclinic.org)igher risk of trabeculectomy failure due to elevated IOP. (visionmonday.com) ### What does “failure” mean here? Not every trabeculectomy failure is the same. In this paper, the standout association was failure from high postoperative IOP — meaning the bleb or drainage pathway did not keep pressure controlled well enough after surgery. That is important because it points less to random bad luck and more to the surgery’s core job not holding up. (ajo.com) ### How big was the effect? The number people will remember is the hazard ratio: 2.87. In plain English, eyes exposed to brimonidine before surgery had almost triple the risk of high-IOP failure compared with eyes without that exposure. That is big enough to change how a glaucoma surgeon thinks during pre-op planning — especially when the alternative explanation, simple noise in a small dataset, is weaker here because the cohort was 501 eyes. (medbrevia.com) ### Why would a pressure-lowering drop hurt a pressure-lowering surgery? The likely issue is not the drug’s short-term pressure effect. It is the ocular surface it leaves behind. Surgeons have worried for years that long exposure to topical glaucoma meds — especially preserved drops — can inflame conjunctival tissue and make filtration surgery scar down faster. Think of it (medbrevia.com) repeatedly irritated. This brimonidine paper does not prove mechanism, but it fits that broader story. (pmc.ncbi.nlm.nih.gov) ### Is this totally out of nowhere? Not really — but it is more specific than the older literature. A 2024 Scientific Reports study showed that heavier cumulative preoperative exposure to glaucoma drops, measured with a medication-intensity index, predicted worse long-term trabeculectomy outcomes. The new paper sharpens that broader warning into a drug-level signal around brimonidine. (pmc.ncbi.nlm.nih.gov) ### Is there any conflicting wrinkle? Yes. Older work suggested a very short preoperative course of topical brimonidine can reduce bleeding and subconjunctival hemorrhage during trabeculectomy. But that is a different question. A couple of drops right before surgery to constrict vessels is not the same thing as chronic preoperative exposure over months or years. Those findings can coexist. (pubmed.ncbi.nlm.nih.gov) ### So what should clinicians do with this? The paper is not a guideline and it does not prove causation. But it is strong enough to raise a practical question before filtration surgery: if a patient is on brimonidine, should that regimen be changed ahead of time when feasible? The answer will depend on disease severity and what substitute options exist. The bottom line is simple (pubmed.ncbi.nlm.nih.gov)rt of the surgical risk profile itself. (ajo.com)
